5-HT(1F) receptor agonists inhibit neurogenic dural inflammation in guinea pigs

NeuroReport

Volumn 8, Issue 9-10, 1997, Pages 2237-2240

  Johnson, Kirk W ^a   Schaus, John M ^a   Durkin, Margaret M ^b   Audia, James E ^a   Kaldor, Stephen W ^a   Flaugh, Michael E ^a   Adham, Nika ^b   Zgombick, John M ^b   Cohen, Marlene L ^a   Branchek, Theresa A ^b   Phebus, Lee A ^a  

^a ELI LILLY AND COMPANY   (United States)

^b H LUNDBECK A S   (Denmark)

Author keywords

Migraine; Receptor localization; Saphenous vein; Serotonin receptor; Trigeminal; Vasoconstriction

Indexed keywords

RECEPTOR SUBTYPE; SEROTONIN 1B RECEPTOR; SEROTONIN 1D RECEPTOR; SEROTONIN 1F RECEPTOR; SEROTONIN RECEPTOR; 4 FLUORO N (3 (1 METHYL 4 PIPERIDINYL) 1H INDOL 5 YL)BENZAMIDE; 4-FLUORO-N-(3-(1-METHYL-4-PIPERIDINYL)-1H-INDOL-5-YL)BENZAMIDE; BENZAMIDE DERIVATIVE; CARBAZOLE DERIVATIVE; INDOLE DERIVATIVE; LY 302148; LY 306258; MESSENGER RNA; NARATRIPTAN; PIPERIDINE DERIVATIVE; PYRAZOLE DERIVATIVE; SEROTONIN AGONIST; TRYPTAMINE DERIVATIVE;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DURA MATER; GUINEA PIG; IN SITU HYBRIDIZATION; MIGRAINE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR DENSITY; SAPHENOUS VEIN; TRIGEMINAL NERVE; VENOCONSTRICTION; ANIMAL; DISEASE MODEL; DRUG EFFECT; INFLAMMATION; MALE; METABOLISM; RABBIT; TRIGEMINUS GANGLION;

ANIMALS; BENZAMIDES; CARBAZOLES; DISEASE MODELS, ANIMAL; GUINEA PIGS; IN SITU HYBRIDIZATION; INDOLES; INFLAMMATION; MALE; PIPERIDINES; PYRAZOLES; RABBITS; RECEPTORS, SEROTONIN; RNA, MESSENGER; SEROTONIN AGONISTS; TRIGEMINAL GANGLION; TRYPTAMINES;

EID: 0030612566     PISSN: 09594965     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001756-199707070-00029     Document Type: Article

References (23)

1. Moskowitz MA. Ann Neurol 16, 157-168 (1984).
2. Shepheard SL, Williamson DJ, Williams J et al. Neuropharmacology 34, 255-261 (1995).
3. Matsubara T, Moskowitz MA and Byun B. Br J Pharmacol 104, 3-4 (1991).
4. Buzzi MG and Moskowitz MA. Cephalalgia 11, 165-168 (1991).
5. Markowitz S, Saito K and Moskowitz MA. J Neurosci 7, 4129-4136 (1987).
6. Phebus LA, Johnson KW, Stengel PW et al. Life Sci 60, 1553-1561 (1997).
7. Weinshank RL, Zgombick JM, Macchi MJ et al. Proc Natl Acad Sci USA 89, 3630-3634 (1992).
8. Adham N, Kao HT, Schecter LE et al. Proc Natl Acad Sci USA 90, 408-12 (1993).
9. Adham N, Borden LA, Schechter LE et al. Naunyn Schmiedeberg's Arch Pharmacol 348, 566-575 (1993).
10. Gustafson EL, Durkin MM, Bard JA et al. Br J Pharmacol 117, 657-666 (1996).
11. Grass M. Br J Clin Pract 47, 205-207 (1993).
12. Tansey MJ, Pilgrim AJ and Lloyd K. J Neurol Sci 114, 109-116 (1993).
13. Humphrey PP, Feniuk W, Perren MJ et al. Br J Pharmacol 94, 1123-1132 (1988).
14. Buzzi MG and Moskowitz MA. Br J Pharmacol 99, 202-206 (1990).
15. Peroutka SJ and McCarthy BG. Eur J Pharmacol 163, 133-136 (1989).
16. Yu XJ, Waeber C, Castanon N et al. Mol Pharmacol 49, 761-765 (1996).
17. Bouchelet I, Cohen Z, Case B et al. Mol Pharmacol 50, 219-223 (1996).
18. Kaumann AJ, Frenken M, Posival H et al. Circulation 90, 1141-1153 (1994).
19. MacIntyre PD, Bhargava B, Hogg KJ et al. Circulation 87, 401-405 (1993).
20. Ottervanger JP and Stricker BH. CNS Drugs 3, 90-98 (1995).
21. Ottervanger JP, Paalman HJ, Boxma GL et al. Lancet 341, 861-862 (1993).
22. Bruinvels AT, Landwehrmeyer B, Gustafson EL et al. Neuropharmacology 33, 367-86 (1994).
23. Waeber C and Moskowitz MA. Naunyn Schmiedeberg's Arch Pharmacol 352, 263-275 (1995).